# MD2, Cystatin C and DNA Methylation Tags as Serum Biomarkers for POCD.

> **NCT03610191** · — · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 250 (estimated)

## Conditions studied

- Postoperative Cognitive Dysfunction

## Interventions

- **DIAGNOSTIC_TEST:** Serum biomarker tests
- **BEHAVIORAL:** Neuropsychological battery tests
- **PROCEDURE:** Cardiac surgery

## Key facts

- **NCT ID:** NCT03610191
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-20
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03610191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03610191, "MD2, Cystatin C and DNA Methylation Tags as Serum Biomarkers for POCD.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03610191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*